Swiss Vaccine Fill-Finish CDMOs (2026)

Switzerland is one of the few countries where vaccine and sterile injectable fill-finish is treated as a strategic national capability rather than a back-end manufacturing step. Lonza, Siegfried, Celonic, and Adragos-owned Baccinex run dedicated aseptic lines for vials, lyophilized product, and pre-filled syringes. The global vaccine contract manufacturing market is projected to grow from USD 4.72 billion in 2025 to USD 5.24 billion in 2026, and Swiss CDMOs are positioned to win an outsized share if they can reach the right buyers.

Why Swiss Fill-Finish Matters Right Now

Switzerland is the world’s second-largest pharmaceutical exporter behind Germany. According to scienceindustries, Swiss chemical and pharmaceutical exports reached a record CHF 152.1 billion in 2025, up 2.2% year over year. The pharmaceutical industry directly employs 50,600 people in Switzerland and contributes 5.8% of GDP, with another 250,200 jobs supported through the supply chain.

Inside that footprint, vaccine and sterile injectable fill-finish has quietly become one of the most contested sub-sectors. Three forces are converging:

• Biologics growth. The large molecule segment now represents the majority of new sterile injectable demand, including monoclonal antibodies, mRNA platforms, conjugates, and protein-based vaccines.
• Capacity rebalancing. Post-COVID, pharma companies are diversifying away from single-region fill-finish toward European GMP-Annex-1-compliant sites with Swissmedic and FDA dual qualification.
• Specialty modalities. Antibody-drug conjugates (ADCs), pre-filled syringes, and lyophilized clinical product all require fill suites that few CDMOs can offer at scale.

For a Swiss CDMO with sterile capacity, this is the most favorable demand environment in a decade. The bottleneck is no longer technical credibility. It is commercial reach into the buying committees of 300+ global biopharma sponsors who decide who runs their drug product.

The Four Anchors of Swiss Vaccine Fill-Finish

Lonza Stein

Lonza is the world’s largest biologics CDMO and is building one of the most significant new fill-finish facilities in Europe. The company announced a CHF 500 million investment to establish a large-scale commercial drug-product fill-and-finish facility in Stein, Switzerland, supporting commercial supply across vials and syringes. Construction is on the same campus as Lonza’s existing clinical drug-product operation, expanding the site’s integrated end-to-end footprint for sponsors who want development and commercial fill in one place.

Beyond Stein, Lonza delivered a strong 2025. The company reported sales of CHF 6.5 billion with +21.7% constant-currency growth and a CORE EBITDA margin of 31.6%. Integrated Biologics, the unit that houses most of the fill-finish demand, grew +32.2%. CEO Wolfgang Wienand described 2025 as “a strong year for the One Lonza team, marked by significant revenue growth with expanding profitability alongside tangible progress on our transformation journey.” For 2026, Lonza guides to 11 to 12% CER sales growth with a CORE EBITDA margin above 32%.

Siegfried (Zofingen HQ, Hameln drug-product)

Siegfried Holding is headquartered in Zofingen and operates a global drug-product network. Its sterile fill-finish operations include aseptic filling of ampoules, vials (2-250ml), pre-filled syringes, and cartridges, with the Hameln site in Germany acting as the core sterile drug-product hub for both biologics and small molecules. The company is adding two new manufacturing lines at Hameln for pre-filled syringes and cartridges, with the first line expected to generate revenue in 2026 and the second in 2027. For Swiss sponsors and global biotechs that want a Swiss-headquartered, EU-anchored sterile partner, Siegfried is one of the most predictable choices on the continent.

Celonic (Basel)

Celonic is a Basel-headquartered biologics CDMO that runs a next-generation Biologics Development Center and pilot plant in Basel, expanding process intensification and perfusion capabilities for biologic drug substance. In October 2025, Celonic and CARBOGEN AMCIS announced a strategic alliance for an integrated ADC development and manufacturing platform, combining Celonic’s biologics manufacturing with CARBOGEN AMCIS’s payload synthesis, conjugation, and sterile fill-finish. For ADC innovators, this is one of the few end-to-end Swiss-based platforms.

Adragos Pharma (Baccinex, Courroux)

Adragos Pharma acquired Baccinex in November 2024, a Swiss sterile fill-finish specialist based in Courroux, Jura. Baccinex brings more than 20 years of aseptic experience in liquid and lyophilized vials, operating from an EU-GMP and US-FDA certified site. According to Adragos founder and CEO Dr. Andreas Raabe, the acquisition “represents a significant milestone for Adragos. Baccinex’s proven expertise in sterile liquids and lyophilization, combined with its operational excellence, enhances our ability to provide integrated solutions from development through to commercial supply.” The Courroux site fills a gap for sponsors who need clinical-to-commercial sterile capacity without booking into the largest CDMO queues.

The Vaccine Fill-Finish Market Behind These Investments

Why are four serious players pouring capital into Swiss sterile capacity at the same time? The numbers explain it.

According to Precedence Research, the global vaccine contract manufacturing market is forecast to grow from USD 4.72 billion in 2025 to USD 12.26 billion by 2034, a CAGR of 11.20%. Europe currently holds roughly 29% of global market share, behind North America at 42% and Asia-Pacific at 24%, supported by EMA-led regulatory rigor and an established biopharma infrastructure.

The broader sterile injectables CDMO market is even larger, with multiple research firms putting 2025 size between USD 15.6 billion and USD 37.8 billion depending on scope, and large molecules accounting for 61.4% of revenue in 2025. Whichever methodology you accept, the trajectory is the same: aseptic fill-finish demand is structurally outrunning supply, and the buyers are global.

That demand is exactly the problem Swiss fill-finish CDMOs need to convert into pipeline. Building a CHF 500 million facility is not the hard part anymore. Reaching the 300 to 500 sponsors who will commit volume to it over the next decade is.

Why Conventional Sales Channels Are Failing Swiss Fill-Finish CDMOs

Sterile fill-finish is sold the way it was sold 20 years ago: at trade fairs, through scientific advisors, and via long-term distributor or partner relationships. Each of those channels is showing diminishing returns.

CPhI Worldwide, BIO, DCAT, and Interphex. CPhI Frankfurt 2025 drew 62,000 attendees from 166 countries and 2,400 exhibiting firms, making it the largest CPhI Europe edition to date. DCAT Week and BIO International add another two anchor events per year. A booth at any of these costs USD 15,000 to 50,000 before travel, staffing, and content. You meet whoever walks past, often procurement contacts, rarely the CMC leads, quality directors, and supply-chain heads who actually shortlist sterile suppliers. Cost per qualified lead: USD 300 to 900+.

KOL and scientific advisor networks. Fill-finish has always been sold partly on trust between technical operators. KOLs and scientific advisors open doors, but each relationship takes months to build and covers one narrow modality. You cannot KOL-network into 200 accounts in parallel.

Distributor and broker relationships. Brokers and intermediaries find their margin in opacity. They own the customer relationship, hide who the end sponsor is, and switch suppliers when a cheaper aseptic slot opens up elsewhere. You lose the account without warning and never learn why.

Field sales representatives. A pharma-experienced BD rep covering one European market costs USD 100,000 to 150,000 annually fully loaded. To cover Germany, France, Italy, the UK, the US, and Asia, you need six. Most mid-sized Swiss CDMOs cannot hire and retain that team. Cost per qualified lead: USD 500 to 1,200+.

Cold calling across borders. Reaching a buying committee at a single biopharma sponsor requires touching procurement, CMC, quality assurance, and regulatory affairs. That is 20+ targeted touches per account in the buyer’s native language with deep GMP credibility. Finding fluent German, French, Italian, Japanese, and English-speaking callers with sterile manufacturing fluency at scale is nearly impossible.

Print and trade-journal advertising. Still bought out of habit. Read by almost no one inside a sponsor’s CMC team.

The structural flaw is the same in every channel: they reach one person at a time in an industry where supplier selection involves five to eleven stakeholders per account, according to Gartner research on B2B buying groups.

What Multi-Threaded Outbound Looks Like for a Sterile CDMO

A modern AI-powered outbound engine treats a target sponsor as a buying committee, not a contact. For a Swiss vaccine fill-finish CDMO, that means parallel, role-specific outreach across:

• CMC leads and drug-product directors receive technical content on your filling formats, isolator technology, lyo cycles, and Annex 1 readiness.
• Quality and regulatory affairs heads receive audit history, Swissmedic and FDA inspection track record, and DMF/CEP support.
• Procurement and supply-chain managers receive capacity, lead-time, and dual-source positioning.
• Project managers and outsourcing leads receive case examples and onboarding timelines.

Around those role-based messages, the engine layers signal detection. When a target sponsor announces a Phase III readout, a new vaccine candidate, a facility delay, or a procurement leadership change, your outreach lands the same week. When a competitor CDMO publishes a capacity warning, your engine flags every sponsor likely affected.

This is where the cost curve flips. Trade fairs and field sales scale linearly: every new market needs another booth or another rep. An AI outbound engine scales sub-linearly. The second 1,000 prospects cost less to reach than the first 1,000, because targeting, sequencing, and content libraries compound over time. Cost per qualified lead with AI outbound: USD 150 to 300, declining as the system learns which messaging works for biologics versus vaccines versus ADCs.

Where Swiss Vaccine Fill-Finish CDMOs Can Win Quickly

Three positioning angles are open right now to any Swiss CDMO with sterile capacity:

1. Annex 1 readiness. EU GMP Annex 1 took effect with full enforcement in 2024, and sponsors are still rebuilding their supplier maps around it. CDMOs with isolators, contamination control strategies, and fully documented Annex 1 alignment have an immediate story.
2. Dual-source for North American sponsors. US biotechs facing capacity bottlenecks at home want a Swiss site with FDA inspection history. The pitch writes itself if the buyer ever hears it.
3. ADC and conjugate fill capability. The Celonic / CARBOGEN AMCIS alliance, Lonza’s existing ADC filling line at Stein, and Baccinex’s lyo capability all point to the same demand wave. Sponsors with ADC programs need partners who can run the full conjugation-to-fill workflow.

Each of these angles is a wedge for a structured outbound program into a finite list of 200 to 500 global sponsors. The technology stack to run those programs at Swiss-quality discretion already exists.

How to Approach This Without Disrupting Your Operations

Switzerland’s pharmaceutical sector has its own pace and its own norms. Fill-finish CDMOs do not want to bolt on a US-style outbound machine that risks brand damage or compliance exposure. The path forward should be quieter:

1. Define the ICP precisely. Vaccine sponsors, ADC innovators, biologics start-ups, and large-molecule pharma each have different buying committees. Pick the lane.
2. Map 300 target sponsors and their committees. Five to eleven contacts each, validated, with current roles.
3. Stage the technical content. Annex 1 compliance summaries, FDA inspection track record, capacity windows, and modality-specific data sheets ready for digital delivery.
4. Run multi-threaded campaigns in the buyer’s language. German, French, English, and Japanese where the sponsor sits.
5. Measure response by role, modality, and signal type. Iterate quarterly.

papaverAI runs this stack for B2B manufacturers. Our case studies show what the operational rhythm looks like when the engine is live. If you want to see whether the model fits a Swiss sterile CDMO setup, get in touch.

Related Reading

• Switzerland Manufacturing Exports: Growth Guide (2026)
• Swiss Pharma & Biotech: Export Guide (2026)

Frequently Asked Questions

How big is the Swiss vaccine fill-finish CDMO market in 2026?

The global vaccine contract manufacturing market is forecast at USD 5.24 billion in 2026, growing at 11.20% CAGR to USD 12.26 billion by 2034. Switzerland sits inside Europe’s 29% share of that global market and is overweight in high-value sterile injectable and biologics fill, with Lonza, Siegfried, Celonic, and Adragos-owned Baccinex anchoring the sector.

Which Swiss CDMOs handle vaccine and sterile fill-finish at commercial scale?

Lonza in Stein is building a CHF 500 million large-scale commercial fill-finish facility. Siegfried Holding, headquartered in Zofingen, runs its sterile drug-product operations from Hameln, Germany. Celonic in Basel partners with CARBOGEN AMCIS for integrated ADC and sterile fill. Adragos Pharma owns Baccinex in Courroux, Jura, for aseptic vials and lyophilized product.

Why are Swiss CDMOs investing so heavily in fill-finish capacity?

Because biologics and vaccine demand is structurally outrunning supply. The sterile injectables CDMO market grew rapidly through 2025 with large molecules now driving 61.4% of revenue. Post-COVID, sponsors are diversifying away from single-region drug-product supply, and Swiss sites offer Annex 1 readiness, Swissmedic and FDA dual qualification, and deep biologics expertise.

How is AI-powered outbound different from trade fairs for fill-finish CDMOs?

Trade fairs reach whoever walks past your booth, mostly procurement, at USD 300 to 900+ per qualified lead, and they scale linearly. AI outbound maps the full buying committee at 300+ target sponsors, delivers role-specific technical content, and detects buying signals like Phase III readouts or facility delays. Cost per qualified lead starts at USD 150 to 300 and decreases as the engine learns.

Can AI outbound handle the technical depth of sterile manufacturing sales?

Yes, when set up correctly. The engine carries your technical content but does not generate regulatory claims or modify your documents. CMC leads receive your filling formats and Annex 1 alignment. Quality heads receive your inspection history. Procurement receives your capacity and lead-time positioning. Your team owns every technical claim. The engine handles reach, sequencing, and timing.

---

If you run a Swiss vaccine or sterile fill-finish CDMO and want a pipeline that does not depend on CPhI traffic, get in touch with papaverAI.